---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-106641"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-08-17T23:59:59+00:00"
generated_at: "2026-06-29T09:26:36.415923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data

## Summary
- Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.
- Cash and equivalents $56.7M at June 30, 2021, expected to fund operations into Q1 2023.
- ELX-02 Phase 2 CF monotherapy data on track for Q4 2021; combination arm with ivacaftor to start by end of 2021.
- ZKN-013 nominated as lead candidate for RDEB/JEB; IND-enabling GLP studies expected by end of 2021.
- Received up to $2.6M award from Cystic Fibrosis Foundation for oral ribosome modulating agents.

## SEC filing metadata
- accession: 0001104659-21-106641
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-08-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/0001104659-21-106641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/tm2125273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-106641
- JSON: https://secwatch.observer/filing/0001104659-21-106641.json
- Plain text: https://secwatch.observer/filing/0001104659-21-106641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.